Patents by Inventor Valerie M. Weaver

Valerie M. Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for predicting and treating tumors resistant to drug, immunotherapy and radiation
    Patent number: 8257928
    Abstract: The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by downregulating the expression of either protein.
    Type: Grant
    Filed: September 7, 2011
    Date of Patent: September 4, 2012
    Assignee: The Regents of the University of California
    Inventors: Valerie M. Weaver, Kun-Chih Kelvin Tsai
  • NOVEL METHODS FOR PREDICITING AND TREATING TUMORS RESISTANT TO DRUG, IMMUNOTHERAPY AND RADIATION
    Publication number: 20120071341
    Abstract: The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by downregulating the expression of either protein.
    Type: Application
    Filed: September 7, 2011
    Publication date: March 22, 2012
    Applicant: The Regents of the University of California
    Inventors: Valerie M. WEAVER, Kun-Chih Kelvin Tsai
  • Methods for predicting and treating tumors resistant to drug, immunotherapy, and radiation
    Patent number: 8093000
    Abstract: The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by down-regulating the expression of either protein.
    Type: Grant
    Filed: May 11, 2009
    Date of Patent: January 10, 2012
    Assignee: The Regents of the University of California
    Inventors: Valerie M. Weaver, Kun-Chih Kelvin Tsai
  • NOVEL METHODS FOR PREDICTING AND TREATING TUMORS RESISTANT TO DRUG, IMMUNOTHERAPY, AND RADIATION
    Publication number: 20100048414
    Abstract: The present invention relates to methods for prognosis, diagnosis, and treatment of malignant tumors that were treatment resistant. The present invention provides methods of prognosis and diagnosis of multidrug resistant tumors through detection of the expression levels of nuclear co-repressor 2 (“N-CoR2”), histone deacetylases 3 (“HDAC3”), and their associated gene expression biomarkers. The present invention also provides methods of sensitizing tumors to anti-tumor therapeutics by disrupting HDAC3 activation, abrogating the N-CoR2-HDAC3 interaction, inhibiting the activity of either protein, or by down-regulating the expression of either protein.
    Type: Application
    Filed: May 11, 2009
    Publication date: February 25, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA A CALIFORNIA CORPORATION
    Inventors: Valerie M. Weaver, Kun-Chih Kelvin Tsai
  • Method for restoration of normal phenotype in cancer cells
    Patent number: 6123941
    Abstract: A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying .beta..sub.1 integrin function-blocking antibody to the cells. The method can be used to assess the progress of cancer therapy. Human breast epithelial cells were shown to be particularly responsive.
    Type: Grant
    Filed: April 28, 1998
    Date of Patent: September 26, 2000
    Assignee: The Regents of the University of California
    Inventors: Mina J. Bissell, Valerie M. Weaver
  • Restoration of normal phenotype in cancer cells
    Patent number: 5846536
    Abstract: A method for reversing expression of malignant phenotype in cancer cells is described. The method comprises applying .beta..sub.1 integrin function-blocking antibody to the cells. The method can be used to assess the progress of cancer therapy. Human breast epithelial cells were shown to be particularly responsive.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: December 8, 1998
    Assignee: The Regents of the University of California
    Inventors: Mina J. Bissell, Valerie M. Weaver